Street Bullish on Ce­ment, In­fra, Auto and Banks

Fund man­agers and an­a­lysts participating in an ET Mar­kets Poll ex­pect the Nifty to gain fur­ther by the year end. 58% of par­tic­i­pants feel the in­dex could ad­vance as much as 8% to 10% to 9,4009,600 by De­cem­ber. Nifty could rise to 9,000 to 9,400 by the yea

The Economic Times - - Companies: Pursuit Of Profit -

DID DE­CEM­BER QUAR­TER EARN­INGS RE­FLECT THE REAL IM­PACT OF DE­MON­ETI­SA­TION? steady as the com­pany’s fi­nan­cials health­care com­pa­nies in the marBe­fore Dr Lal list­ing, VRL look promis­ing,”saidKun­jBansal,ED kets,” said Dharmesh Me­hta, manL­o­gis­tics’ de­but in April at a pre­miand chief in­vest­ment of­fi­cer at ag­ing di­rec­tor and CEO of Axis um of 40% to its is­sue price was the Mum­bai: Drug maker Alkem Cen­trumWealthMan­age­ment. Cap­i­tal. “We have seen that if the strong­est. Inox Wind and Syn­gene Lab­o­ra­to­ries and di­ag­nos­tic BIG­GEST chain SURPRISEOn Dr IN Lal THE PathLabs,BUD­GET Bansal NIFTY­said DECEMBERIPOs is at­trac­tively2017 TAR­GET priced, there is In­ter­na­tional IPOs listed at a preDrLalPathLab­s­madestel­larde­but­sNo hike in STT and no LTCG Tax val­u­a­tion of the com­pany ap­pears lot to be made by in­vestors. There is mium of 35% and 24%, re­spec­tively. on the ex­changes on Wed­nes­day. ex­pen­sive af­ter the strong list­ing de­mand­for­pa­per­swhere­pro­mot­ers In­terGlobe Avi­a­tion, the op­er­a­tor of Alkem listed 31% above its No is­sue neg­a­tives and in­vestors should wait for the have good track record.” In­digo, which listed at al­most 12% price,whileDrLalPathLab­sopenedNo pop­ulist mea­sure com­pany’s fi­nan­cials now. Narayana Hru­day­alaya’s IPO — pre­mium to its IPO price of Rs760, is at a 50% pre­mium — the best list­ing On Wed­nes­day’s clos­ing price, the last share sale in 2015 which cur­rently trad­ing 55% above its is

Main­tain­ing fis­cal pru­dence BIG­GEST DIS­AP­POINT­MENT IN THE BUD­GET in 2015 — as in­vestors who failed to Alkem’s mar­ket cap­i­tal­i­sa­tion is close­donMon­day—was­sub­scribed sue price. get shares in the of­fer­ings lapped Oth­ers₹ 16,500 crore, trail­ing be­hind 8.63 times. them up on the open­ing day. The Wock­hardt at ₹ 17,371 crore. Alem­bic Low­er­ing The IPO10% sur­chage­mar­ket in 2015 Agri has witNo hike in strong WILL twin RBI list­ingsCUT en­sured that HOWthe MUCH Pharma? is val­ued at ₹ 13,000 crore.

cor­po­rate tax nessed on its salarybest run since 2010. spend Most is­tax slab pri­ma­ryRATES NEXT mar­ket’s WEEK? win­ning run Sun Pharma, the leader of the phar­sues have

above fetched50 lakh strong list­ing gains through 2015. ma pack, has mar­ket cap­i­tal­i­sa­tion forin­vestors.SHKelka­randCo,as­peAlkemYes closed at ₹ 1,381 No on the BSE, of ₹ 1.90 lakh crore.25 bps

SEC­TORS cialty fragrance SECTORSand flavour in­grediLARGE CAPS up31.5%over­it­sis­suepriceof ₹ 1,050 Alkem raised about ₹ 1,350 crore THAT WILLent maker, which THAT listed WILLin Novem­ber, THAT WILL per share af­ter touch­ing a high of from its IPO, which was sub­scribed opened23%aboveit­sIPOprice.

OUT­PER­FORM UNDEROUTPERFORM ₹ 1,410. Dr Lal closed at ₹ 824 over its 44.29 times, while Dr Lal’s ₹ 638-crore The­strong­per­for­mance­saugur­well

IN 2017 PER­FORM IN IN 2017 is­sue price of ₹ 550. is­sue was sub­scribed50 bps 33.41 times. for the IPO mar­ket in 2016, when a

Money man­agers said gains in The suc­cess of is­sues such as Ce­ment strong pipe­line of 2017 com­pa­nies would Asian Paints both the shares are likely to be Alkem Labs and Dr Lal Path Labs In­fra look to raise money Pharma through this Bank of Baroda capped af­ter the strong list­ings. means com­pa­nies have raised more Au­to­mo­biles route,said­bro­ker­sand­bankers.Tele­com HDFC Bank

“Alkem’slist­ing­per­for­mance­wa­son than`13,000crore­so­far­fromthep­riBanks Met­als SBI ex­pect­ed­lines,andwe­ex­pect­the­stock mary mar­ket in cal­en­dar 2015. FMCG Oil & Gas Sun Pharma per­for­mance­tore­main­mea­sured­but “There is strong ap­petite for Re­cap of PSU banks Oth­ers

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.